EP0752880A4 - Treatment of autoimmune disease using oral tolerization and/or type i interferon - Google Patents
Treatment of autoimmune disease using oral tolerization and/or type i interferonInfo
- Publication number
- EP0752880A4 EP0752880A4 EP95916183A EP95916183A EP0752880A4 EP 0752880 A4 EP0752880 A4 EP 0752880A4 EP 95916183 A EP95916183 A EP 95916183A EP 95916183 A EP95916183 A EP 95916183A EP 0752880 A4 EP0752880 A4 EP 0752880A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- interferon
- treatment
- type
- autoimmune disease
- oral tolerization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rehabilitation Therapy (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22537294A | 1994-04-08 | 1994-04-08 | |
US225372 | 1994-04-08 | ||
PCT/US1995/004120 WO1995027499A1 (en) | 1994-04-08 | 1995-04-07 | Treatment of autoimmune disease using oral tolerization and/or type i interferon |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0752880A1 EP0752880A1 (en) | 1997-01-15 |
EP0752880A4 true EP0752880A4 (en) | 2000-08-09 |
Family
ID=22844605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95916183A Withdrawn EP0752880A4 (en) | 1994-04-08 | 1995-04-07 | Treatment of autoimmune disease using oral tolerization and/or type i interferon |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0752880A4 (en) |
JP (1) | JPH09511745A (en) |
AU (1) | AU686797B2 (en) |
BR (1) | BR9507451A (en) |
CA (1) | CA2185353A1 (en) |
HU (1) | HUT74900A (en) |
IL (1) | IL113303A0 (en) |
NO (1) | NO964199D0 (en) |
WO (1) | WO1995027499A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5906816A (en) * | 1995-03-16 | 1999-05-25 | University Of Florida | Method for treatment of autoimmune diseases |
US6372206B1 (en) | 1989-03-02 | 2002-04-16 | University Of Florida | Orally-administered interferon-TAU compositions and methods |
CZ122697A3 (en) * | 1994-10-25 | 1997-09-17 | Immulogic Pharma Corp | Preparations and methods of treating disseminated sclerosis |
SK284989B6 (en) * | 1996-12-24 | 2006-04-06 | Biogen, Inc. | Liquid composition comprising interferon and method for stabilizing interferon |
JP2001511187A (en) * | 1997-02-28 | 2001-08-07 | エンゾー セラピュウティクス, インコーポレイテッド | Novel process for selective immune down-regulation (SIDR) |
EP2322216A1 (en) | 1997-03-21 | 2011-05-18 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient |
US6812205B2 (en) | 2000-03-15 | 2004-11-02 | The Brigham & Women's Hospital, Inc. | Suppression of vascular disorders by mucosal administration of heat shock protein peptides |
ATE367823T1 (en) | 2000-05-24 | 2007-08-15 | Us Health | E-SELECTIN TO TREAT OR PREVENT STROKE |
WO2004058295A1 (en) * | 2002-12-26 | 2004-07-15 | Daiichi Suntory Pharma Co., Ltd. | Remedy for pemphigoid |
US8920808B2 (en) | 2006-10-31 | 2014-12-30 | East Carolina University | Cytokine-based fusion proteins for treatment of multiple sclerosis |
AU2010234743A1 (en) * | 2009-03-31 | 2011-10-20 | East Carolina University | Cytokines and neuroantigens for treatment of immune disorders |
JP6590330B2 (en) * | 2013-11-11 | 2019-10-16 | キッコーマン株式会社 | Oral immune tolerance enhancing substance screening method and oral immune tolerance enhancing composition |
GB201904767D0 (en) | 2019-04-04 | 2019-05-22 | Orexo Ab | New pharmaceutical compositions |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0325471A1 (en) * | 1988-01-22 | 1989-07-26 | Collagen Corporation | Method for suppressing the growth of normal and cancer cells |
WO1993016724A1 (en) * | 1992-02-28 | 1993-09-02 | Autoimmune, Inc. | Bystander suppression of autoimmune diseases |
-
1995
- 1995-04-07 EP EP95916183A patent/EP0752880A4/en not_active Withdrawn
- 1995-04-07 BR BR9507451A patent/BR9507451A/en unknown
- 1995-04-07 JP JP7526403A patent/JPH09511745A/en active Pending
- 1995-04-07 IL IL11330395A patent/IL113303A0/en unknown
- 1995-04-07 AU AU22776/95A patent/AU686797B2/en not_active Ceased
- 1995-04-07 HU HU9602750A patent/HUT74900A/en active IP Right Revival
- 1995-04-07 WO PCT/US1995/004120 patent/WO1995027499A1/en active Search and Examination
- 1995-04-07 CA CA002185353A patent/CA2185353A1/en not_active Abandoned
-
1996
- 1996-10-03 NO NO964199A patent/NO964199D0/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0325471A1 (en) * | 1988-01-22 | 1989-07-26 | Collagen Corporation | Method for suppressing the growth of normal and cancer cells |
WO1993016724A1 (en) * | 1992-02-28 | 1993-09-02 | Autoimmune, Inc. | Bystander suppression of autoimmune diseases |
Non-Patent Citations (1)
Title |
---|
See also references of WO9527499A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP0752880A1 (en) | 1997-01-15 |
JPH09511745A (en) | 1997-11-25 |
CA2185353A1 (en) | 1995-10-19 |
BR9507451A (en) | 1997-08-05 |
HUT74900A (en) | 1997-02-28 |
HU9602750D0 (en) | 1996-11-28 |
AU686797B2 (en) | 1998-02-12 |
IL113303A0 (en) | 1995-07-31 |
AU2277695A (en) | 1995-10-30 |
WO1995027499A1 (en) | 1995-10-19 |
NO964199L (en) | 1996-10-03 |
NO964199D0 (en) | 1996-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB9609932D0 (en) | Use of IL-12 and IFN alpha for the treatment of infectious diseases | |
ZA907564B (en) | Treatment of conditions and disease | |
IL131025A0 (en) | Treatment of autoimmune disease using tolerization in combination with methotrexate | |
IL113303A0 (en) | Treatment of autoimmune disease using oral tolerization and/or type I interferon | |
IL113301A0 (en) | Treatment of autoimmune disease using oral tolerization and/or TH2-enhancing cytokines | |
HUP9900147A3 (en) | Therapeutic agents and autoimmune diseases | |
GB9419553D0 (en) | Polypeptides and their use in the treatment of auto-immune disease | |
HUP0003244A2 (en) | Novel triptolide derivatives useful in the treatment of autoimmune diseases and pharmaceutical compositions thereof | |
HUP9800829A3 (en) | Collagen-based methods and formulations for the treatment of immune system-mediated diseases | |
PL322002A1 (en) | Variants of human dnase i | |
GB9611500D0 (en) | Prevention and treatment of oral conditions with peptides having anti-adherence activity | |
IL112681A0 (en) | Opioid peptides for the treatment of pain and use thereof | |
EP0833641A4 (en) | Treatment and prevention of prostatic disease | |
EP0540575A4 (en) | Human meg-csf protein and methods | |
GB9516572D0 (en) | Prevention and/or treatment of disease | |
NZ277605A (en) | Human stanniocalcin-alpha polypeptide and dna (rna) encoding polypeptide; polypeptide may be derived from atcc 75861 | |
IL115017A0 (en) | Methods of maintaining teeth and oral bone | |
ZA97210B (en) | Oral administration of effective amunts of forms of hyaluronic acid | |
EG20171A (en) | Treatment of conditions and disease | |
ZA951440B (en) | Novel opiold peptides for the treatment of pain and use thereof | |
PL342649A1 (en) | Prevention of amyloidogenous diseases and treatment of them | |
GB9419549D0 (en) | Polypeptides and their use in the treatment of auto-immune disease | |
AU3163795A (en) | Treatment of autoimmune diseases | |
BG99596A (en) | Preparation for the treatment of gums and teeth | |
BG97113A (en) | Preparation for treatment of inflammations of the oral mucous membrane and parodonta gingivittancort |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19960912 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20000627 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 38/17 A, 7A 61K 38/28 B, 7A 61K 38/39 B, 7A 61K 38/26 B, 7A 61K 38/21 B, 7A 61K 38/21 J, 7A 61K 38:26 J, 7A 61K 38:28 J, 7A 61K 38:39 J |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20000915 |